Want to see HK:6896 full AI Analyst Report?
Golden Throat Holdings Group Co Ltd (6896) AI Stock Analysis
Top Page
Golden Throat Holdings Group Co Ltd
(HKEX:6896)
The overall score is driven primarily by strong underlying profitability and a solid balance sheet, but is held back by a sharp weakening in 2025 cash flow and higher leverage, along with very weak price action and bearish technical signals. Attractive valuation, with a low earnings multiple and high dividend yield, provides a meaningful positive offset but does not fully outweigh the recent deterioration in cash generation and the current downtrend in the share price.
Golden Throat Holdings Group Co Ltd (6896) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.44B
- Dividend Yield
- 17.44%
- Average Volume (3M)
- 539.41K
- Price to Earnings (P/E)
- 5.8
- Beta (1Y)
- 0.14
- Revenue Growth
- -5.37%
- EPS Growth
- -18.03%
- Country
- Hong Kong
- Employees
- 824
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Golden Throat Holdings Group Co Ltd Business Overview & Revenue Model
Company Description
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China...
How the Company Makes Money
Golden Throat Holdings Group Co Ltd makes money primarily by selling branded throat lozenges (and any related products within its portfolio) to wholesalers, distributors, and retailers, who then sell to end consumers. The company’s core revenue strea...
Golden Throat Holdings Group Co Ltd Financial Statement Overview
Summary
Score reflects strong profitability with high gross and net margins and solid returns on equity supported by a stable balance sheet, offset by rising leverage and a sharp deterioration in 2025 operating cash flow.
Income Statement
82Very PositiveBalance Sheet
75PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 904.47M | 943.26M | 1.19B | 961.38M | 992.01M | 820.54M |
| Gross Profit | 673.07M | 717.01M | 894.18M | 697.72M | 720.92M | 577.74M |
| EBITDA | 299.10M | 340.56M | 456.65M | 410.75M | 424.93M | 281.80M |
| Net Income | 215.18M | 251.20M | 318.63M | 250.16M | 281.22M | 187.64M |
Balance Sheet | ||||||
| Total Assets | 2.13B | 2.29B | 2.25B | 2.30B | 2.30B | 1.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.08B | 1.14B | 1.07B | 925.51M | 802.84M |
| Total Debt | 711.15M | 584.52M | 426.92M | 412.34M | 272.59M | 235.00M |
| Total Liabilities | 934.48M | 912.77M | 784.87M | 748.34M | 760.18M | 588.04M |
| Stockholders Equity | 1.20B | 1.38B | 1.47B | 1.55B | 1.54B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 173.66M | 77.99M | 408.65M | 221.30M | 255.30M | 116.23M |
| Operating Cash Flow | 215.82M | 123.31M | 475.87M | 238.84M | 271.15M | 164.89M |
| Investing Cash Flow | -110.99M | -55.02M | -41.60M | -59.67M | 36.59M | -145.11M |
| Financing Cash Flow | -169.73M | -228.90M | -335.18M | -79.38M | -142.01M | -10.21M |
Golden Throat Holdings Group Co Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6896, the sentiment is Neutral. The current price of 1.95 is above the 20-day moving average (MA) of 1.92, below the 50-day MA of 2.05, and below the 200-day MA of 2.82, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 69.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6896.
Golden Throat Holdings Group Co Ltd Peers Comparison
Overall Rating
HK:023977Outperform
HK:263370Outperform- HK:689667.7Neutral
HK:089758.6Neutral
HK:057052.75Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 77Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:2633 | 70Outperform | HKD 1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% |
| HK:6896 | 68Neutral | HKD 1.44B | 5.82 | 16.70% | 17.44% | -5.37% | -18.03% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0570 | 53Neutral | HKD 5.89B | -4.81 | -4.98% | 0.30% | -15.80% | -298.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6896 | Golden Throat Holdings Group Co Ltd | 1.95 | -1.15 | -37.14% | |
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.17 | -1.16 | -49.79% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.94 | -0.42 | -30.74% |
Golden Throat Holdings Group Co Ltd Corporate Events
Golden Throat Grants RMB55 Million Unsecured Loan to Controlling Shareholder
Golden Throat Holdings Group Co Ltd has announced that its wholly owned subsidiary Guangxi Golden Throat will extend a one year unsecured loan of RMB55 million to executive director, general manager and controlling shareholder, Mr. Zeng Yong, for his...
Golden Throat Interim Profit Slumps as Revenue Declines and Margins Tighten
Golden Throat Holdings Group Company Limited reported weaker interim results for the six months ended 30 June 2026, reflecting pressure on its core throat-care business. Revenue fell 12.2% year-on-year to RMB280.1 million, while gross profit declined...
Golden Throat Warns of 43% Interim Profit Drop Amid Higher Promotional Spend
Golden Throat Holdings Group Company Limited, a Hong Kong-listed consumer healthcare group known for its throat products and operating mainly in Guangxi, China, has been intensifying promotional efforts to strengthen its market presence. These initia...
Golden Throat Sets Board Meeting to Approve Interim Results and Consider Dividend
Golden Throat Holdings Group Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026, along with their publication. The board will also consider the declaration...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 25, 2026